Some big blocks being removed, only a matter of time before it gets to 1.30. Many will be watching/attending the ASM later today before they commit, so tomorrow will be interesting.
Printable View
Attended online meeting today. Some points in the Q & A's not covered in released info.
- No NASDAQ listing anticipated currently though constantly under review
- Recovery of old invoice payments not anticipated in budgets and any recovery will be 'cream'. More impt to concentrate on developing ongoing supply relationship.
- No Dividend likelihood in short term.
- Singapore study of 400 patients complete. Likely to be published in next 6 months.
- How strong is IP? Extensive patent portfolio and expenditure on IP is biggest area of expense after wages and patient studies. In addition they claim to have numerous trade secrets "which we don't dare to put into patents."
- USA Lab's current test availability is 260,000 tests pa this at $US760 per test = potential revenue of $US 197 mill.
- Australia hospitals progress is slow. Studies underway.
Above my interpretation only. DYOR.
Thanks Left Field for passing on what you picked up from ASM. Nice start to financial year.
Thanks LF
I like the comment about recovery of old invoices. In my experience, chasing the past is generally an expensive and often fruitless exercise that takes one's eye off present and future opportunities.
As I mentioned earlier we are not on a bullet train with PEB but the track ahead looks pretty clear and there is no reason not to expect most, if not all future announcements to be in the good or great category.
When that USA lab is operating at full capacity the news will be better than great - sensational comes to mind.
The new study soon to be published soon looks interesting. If they get in the guidelines all bets are off. Who wants to be the urologist not using the test if it's in the guidelines?
Would I be wrong in assuming that we are to get quarterly updates from here on?
Would be nice after the paucity of information over the years relative to tests and uptake.
Now it seems to be getting some traction it will make for much more in depth projections.
5300 tests in the 1/4 just gone bodes well for a possible 2 "tens of thousands" of tests.
Couple of years late but never mind.:rolleyes:
Certainly a lot for the new CEO to get his/her teeth into. Paucity of reporting just one.
IMO the change of a CEO is the biggest short term risk ahead for us holders. The ASM was told that a Melbourne head hunting firm are busy looking. I guess that's better than a Dunedin head hunting firm?
Another take from the ASM I forgot to mention was quiet confidence that NZ's proposed changes to a 'national' DHB with 'national standards' will be good for PEB. Seems some DHB's like Otago/Southland just too busy with new buildings, delivering Covid inoculations and stopping babies being born in cars while enroute to distant hospitals, to have time to think about PEB.
Anyways.... onwards and upwards. North of 1.30 next week?
Following the instos, lightened my overweight position and sold a few into the spike, thanks to the 'good' news.
I will not be following the instos and sell any of my overweight position. With a $US 3.5 billion addressable market and a low COGS I will sit tight. I find it hard to be pessimistic with this share and I really do not care if my 25% overweight position turns into a 80% overweight position due to share price appreciation in fact I will be very pleased.